Overall, these results indicate that doxorubicin induced NF-κB nuclear translocation in all tested breast cancer cells, but they showed a differential NF-κB transcriptional response probably refecting their differences at the genetic background. The gene discussed is NFKB1; the disease is breast carcinoma.